Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press6310.17650/2222-8721-2013-0-4-19-23ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯElectron microscopic study of skeletal muscle in the Lambert–Eaton myasthenic syndromeЭлектронно-микроскопическое исследование скелетных мышц при миастеническом синдроме Ламберта–ИтонаBabakovaL. L.БабаковаЛ. Л.
Russian Federation
PozdnyakovO. M.ПоздняковО. М.
Russian Federation
opozdnyakov@rambler.ruThe Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, MoscowФГБУ «НИИ общей патологии и патофизиологии» РАМН, Москва201220133419232002201520022015Copyright ©; 2013, Babakova L.L., Pozdnyakov O.M.Copyright ©; 2013, Бабакова Л.Л., Поздняков О.М.2013Babakova L.L., Pozdnyakov O.M.Бабакова Л.Л., Поздняков О.М.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/63

Skeletal muscle biopsies of 7 patients with Lambert–Eaton syndrome were studied. Revealed that specific changes in the neuromuscular junctions are the complication of the postsynaptic region organization. Along with this, there is a destructive process in axon terminals, which may be terminated by the denervation of muscle fibers. Violations of the structure of muscle fibers were observed. A new hypothesis of the Lambert–Eaton syndrome pathogenesis was preposed.

Исследованы биопсии скелетных мышц 7 больных с синдромом Ламберта–Итона. Выявлено, что специфические изменения в нервно-мышечных синапсах заключаются в усложнении организации постсинаптической области. Наряду с этим наблюдается деструктивный процесс в терминалях аксонов, который может заканчиваться денервацией мышечных волокон. Наблюдаются нарушения структуры мышечных волокон. Предложена новая гипотеза патогенеза синдрома Ламберта–Итона.

Lambert–Eaton myasthenic syndromeultrastructureneuro-muscular junctionskeletal musclepathogenesisмиастенический синдром Ламберта–Итонаультраструктуранервно-мышечный синапсскелетные мышцыпатогенез1. Lambert E.H., Eaton L.M., Rooke E.D. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956;187:612– 3.Lambert E.H., Eaton L.M., Rooke E.D. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956;187:612– 3.2. Eaton L.M., Lambert E.H. Electromyography and electrical stimulation of nerves in diseases of the motor unit: observations on a myasthenic syndrome associated with malignant tumours. JAMA 1957;163:1117–24.Eaton L.M., Lambert E.H. Electromyography and electrical stimulation of nerves in diseases of the motor unit: observations on a myasthenic syndrome associated with malignant tumours. JAMA 1957;163:1117–24.3. Seneviratne U., de Silva R. Lambert–Eaton myasthenic syndrome. Postgrad Med J 1999;75:516–20.Seneviratne U., de Silva R. Lambert–Eaton myasthenic syndrome. Postgrad Med J 1999;75:516–20.4. Kim J.-A., Lim Y.-M., Jang E.-H., Kim K.-K. A patient with coexisting myasthenia gravis and Lambert–Eaton myasthenic syndrome. J Clin Neurol (Seoul, Korea), 2012; 8 (3):235–7.Kim J.-A., Lim Y.-M., Jang E.-H., Kim K.-K. A patient with coexisting myasthenia gravis and Lambert–Eaton myasthenic syndrome. J Clin Neurol (Seoul, Korea), 2012; 8 (3):235–7.5. Newsom-Davis J. Lambert–Eaton myasthenic syndrome. Rev Neurol (Paris). 2004;160(2):177–80;Newsom-Davis J. Lambert–Eaton myasthenic syndrome. Rev Neurol (Paris). 2004;160(2):177–80;6. Donald B. Sanders, Vern C. Juel. Chapter 9 The Lambert–Eaton myasthenic syndrome. Handbook of Clinical Neurology 2008;91:273–83.Donald B. Sanders, Vern C. Juel. Chapter 9 The Lambert–Eaton myasthenic syndrome. Handbook of Clinical Neurology 2008;91:273–83.7. van Sonderen A., Wirtz P.W., Verschuuren J.J., Titulaer M.J. Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. Curr Treat Options Neurology 2013;15 (2):224–39.van Sonderen A., Wirtz P.W., Verschuuren J.J., Titulaer M.J. Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. Curr Treat Options Neurology 2013;15 (2):224–39.8. Wu X., Wang J., Liu Y., Liu K. Clinical presentation and differential diagnosis of Lambert– Eaton myasthenic syndrome. Neurosciences (Riyadh, Saudi Arabia) 2013;18(2):169–72.Wu X., Wang J., Liu Y., Liu K. Clinical presentation and differential diagnosis of Lambert– Eaton myasthenic syndrome. Neurosciences (Riyadh, Saudi Arabia) 2013;18(2):169–72.9. Engel A.G., Santa T. Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann N Y Acad Sci 1971;183:46–63.Engel A.G., Santa T. Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann N Y Acad Sci 1971;183:46–63.10. Santa T., Engel A.G., Lambert E.G. Histometric study of neuromuscular junction ultrastructure. II. Myasthenic syndrome. Neurology 1972;22(4):370–6.Santa T., Engel A.G., Lambert E.G. Histometric study of neuromuscular junction ultrastructure. II. Myasthenic syndrome. Neurology 1972;22(4):370–6.11. Бабакова Л.Л., Коломенская Е.А., Островская Н.В., Поздняков О.М. Исследование ультраструктуры нервно-мышечных синапсов при миастеническом синдроме Ламберта–Итона. Бюлл экспер биол и мед 1976;1:79–80.Бабакова Л.Л., Коломенская Е.А., Островская Н.В., Поздняков О.М. Исследование ультраструктуры нервно-мышечных синапсов при миастеническом синдроме Ламберта–Итона. Бюлл экспер биол и мед 1976;1:79–80.12. Tsujihata M., Kinoshita I., Mori M. et al. Ultrastructural study of the motor end-plate in botulism and Lambert–Eaton myasthenic syndrome. J Neurol Sci 1987;81(2–3):197– 213.Tsujihata M., Kinoshita I., Mori M. et al. Ultrastructural study of the motor end-plate in botulism and Lambert–Eaton myasthenic syndrome. J Neurol Sci 1987;81(2–3):197– 213.13. Hesselmans L.F., Jennekens F.G., Kartman J. et al. Secondary changes of the motor endplate in Lambert–Eaton myasthenic syndrome: a quantitative study. Acta Neuropathol 1992;83(2):202–6.Hesselmans L.F., Jennekens F.G., Kartman J. et al. Secondary changes of the motor endplate in Lambert–Eaton myasthenic syndrome: a quantitative study. Acta Neuropathol 1992;83(2):202–6.14. Бабакова Л.Л., Коломенская Е.А., Кузьмин Н.В., Поздняков О.М. Ультраструктурная характеристика трубчатых агрегатов в скелетных мышцах человека. Арх патол 1974;36(4):50–6.Бабакова Л.Л., Коломенская Е.А., Кузьмин Н.В., Поздняков О.М. Ультраструктурная характеристика трубчатых агрегатов в скелетных мышцах человека. Арх патол 1974;36(4):50–6.15. O’Neill J.H., Murray N.M., Newsom-Davis J. The Lambert–Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577–96.O’Neill J.H., Murray N.M., Newsom-Davis J. The Lambert–Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577–96.16. Snutch T.P., Reiner P.B. Ca2+ channels: diversity of form and function. Curr Opin Neuorbiol 1992;2:247–53.Snutch T.P., Reiner P.B. Ca2+ channels: diversity of form and function. Curr Opin Neuorbiol 1992;2:247–53.17. Varadi G, Mori Y, Mikala G, Schwartz A. Molecular determinants of Ca2+ channel function and drug action. Trends Pharmacol Sci 1995;16:43–9.Varadi G, Mori Y, Mikala G, Schwartz A. Molecular determinants of Ca2+ channel function and drug action. Trends Pharmacol Sci 1995;16:43–9.18. Hong S.J., Chang C.C. Inhibition of ace - tylcholine release from mouse motor nerve by a P-type calcium channel blocker omega-agatoxin IVA. J Physiol (Lond) 1995;482: 283–90.Hong S.J., Chang C.C. Inhibition of ace - tylcholine release from mouse motor nerve by a P-type calcium channel blocker omega-agatoxin IVA. J Physiol (Lond) 1995;482: 283–90.19. Bowersox S.S., Miljanich G.P., Sugiura Y. et al. DiVerential blockade of voltage-sensitive calcium channels at the mouse neuromuscular junction by novel omega-cono peptides and Aga IVA. J Pharmacol Exp Ther 1995;273:248–56.Bowersox S.S., Miljanich G.P., Sugiura Y. et al. DiVerential blockade of voltage-sensitive calcium channels at the mouse neuromuscular junction by novel omega-cono peptides and Aga IVA. J Pharmacol Exp Ther 1995;273:248–56.20. Lennon V.A., Kryzer T.J., Griesmann G.E. et al. Calcium-channel antibodies in the Lambert– Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467–74.Lennon V.A., Kryzer T.J., Griesmann G.E. et al. Calcium-channel antibodies in the Lambert– Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467–74.21. Oguro-Okano M., Griesmann G.E., Wieben E.D. et al. Molecular diversity of neuronal- type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc 1992;67:1150–9.Oguro-Okano M., Griesmann G.E., Wieben E.D. et al. Molecular diversity of neuronal- type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc 1992;67:1150–9.22. Meriney S.D., Hulsizer S.C., Lennon V.A., Grinnel A.D. Lambert–Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996;40:739–49.Meriney S.D., Hulsizer S.C., Lennon V.A., Grinnel A.D. Lambert–Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996;40:739–49.